Penthrox is the brand name of methoxyflurane, a non-opioid analgesic indicated for emergency relief of moderate to severe pain. Credit: Ben Mills via Wikimedia.

At the European Society of Emergency Medicine Congress, UK-based Mundipharma announced positive results from various trials of its analgesic Penthrox (methoxyflurane) for pain relief.

Carried out in Italy, the MEDITA study demonstrated Penthrox was superior to standard analgesic treatment (SAT) – IV morphine for severe pain and IV paracetamol or ketoprofen for moderate trauma pain – in terms of change in pain intensity over ten minutes, the primary endpoint.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Penthrox was also rated as excellent, very good or good by significantly more patients and healthcare professionals than the SAT option. With 72.7% of patients giving one of these positive ratings for Penthrox, compared to 60.9% for the SAT group; while 90.3% of healthcare professionals gave Pethrox a positive rating, compared to 64.4% for the control group.

In the placebo-controlled PenASAP study, which was conducted in France, Penthrox combined with the standard of care group experienced a median time of 35 minutes to pain relief, whereas placebo plus standard of care did not reach the definition of pain relief on the visual analogue scale.

Penthrox use in the elderly caused much quicker pain relief than SAT – 5.5 minutes versus 12.8 minutes, according to results from the Spanish sub-population focused InMEDIATE study. Other results from this trial saw patients with severe trauma-related and acute trauma pain in the Penthrox group experience a greater reduction from baseline than SAT patients at three, five, ten and 20 minutes following administration.

Penthrox is an inhaled non-opioid analgesic indicated for emergency relief of moderate to severe pain in adults with trauma and associated pain. It is currently marketed across 40 European markets, with the exception of the Republic of Ireland and the UK.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mundipharma medical affairs lead Sara Dickerson said: “We are very excited by this data demonstrating the superiority of methoxyflurane when compared directly with standard treatment, or compared with placebo when used in addition to standard of care for moderate-to-severe trauma pain, in real-world settings in European countries.

“We know that trauma pain is too often undertreated, or even untreated, which can be very distressing for patients and can lead to long-term effects. Results from these studies support the use of methoxyflurane as a simple, fast and effective non-opioid treatment option for adult patients experiencing trauma pain.”